These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027 [TBL] [Abstract][Full Text] [Related]
4. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects. Small CB; Margolis DA; Shaefer MS; Ross LL BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804 [TBL] [Abstract][Full Text] [Related]
5. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA Mounzer K; Hsu R; Fusco JS; Brunet L; Henegar CE; Vannappagari V; Stainsby CM; Shaefer MS; Ragone L; Fusco GP AIDS Res Ther; 2019 Jan; 16(1):1. PubMed ID: 30651100 [TBL] [Abstract][Full Text] [Related]
6. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424 [TBL] [Abstract][Full Text] [Related]
7. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV. Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265 [TBL] [Abstract][Full Text] [Related]
8. Successful translation of pharmacogenetics into the clinic: the abacavir example. Phillips E; Mallal S Mol Diagn Ther; 2009; 13(1):1-9. PubMed ID: 19351209 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review. Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250 [TBL] [Abstract][Full Text] [Related]
10. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. Waters LJ; Mandalia S; Gazzard B; Nelson M AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891 [TBL] [Abstract][Full Text] [Related]
11. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Saag M; Balu R; Phillips E; Brachman P; Martorell C; Burman W; Stancil B; Mosteller M; Brothers C; Wannamaker P; Hughes A; Sutherland-Phillips D; Mallal S; Shaefer M; Clin Infect Dis; 2008 Apr; 46(7):1111-8. PubMed ID: 18444831 [TBL] [Abstract][Full Text] [Related]
12. HLA- B*5701 Allele in HIV-infected Indian Children and its Association with Abacavir Hypersensitivity. Manglani MV; Gabhale YR; Lala MM; Sekhar R; More D Indian Pediatr; 2018 Feb; 55(2):140-141. PubMed ID: 29242412 [TBL] [Abstract][Full Text] [Related]
13. [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance]. Arnedo Valero M Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():34-9. PubMed ID: 18680694 [TBL] [Abstract][Full Text] [Related]
14. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? Phillips EJ Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425 [No Abstract] [Full Text] [Related]
15. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676 [TBL] [Abstract][Full Text] [Related]
16. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. Lucas A; Nolan D; Mallal S J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695 [TBL] [Abstract][Full Text] [Related]
17. The convenience of flow cytometry for HLA-B*5701 screening to prevent abacavir hypersensitivity reactions. Airo P; Scarsi M; Malagoli A; Carella G; Izzo I; Carosi G; Torti C J Acquir Immune Defic Syndr; 2009 Jul; 51(3):361-2. PubMed ID: 19553774 [No Abstract] [Full Text] [Related]
18. HLA-B*5701 genetic screening prior to abacavir prescription in Georgia. Dvali N; Chkhartishvili N; Sharvadze L; Karchava M; Tsertsvadze T Georgian Med News; 2010 Dec; (189):16-20. PubMed ID: 21252404 [TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV. Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465 [TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity reactions in patients treated with abacavir: strategies to avoid such reactions. Kapoor S AIDS Patient Care STDS; 2008 Oct; 22(10):769. PubMed ID: 18778242 [No Abstract] [Full Text] [Related] [Next] [New Search]